Other

Sanofi-aventis

Rebecca Pruss

Jean-Pierre Maffrand

Barbara Cordell

Daniel Frehel

Paul De Cointet

Pierre Despeyroux

Ronald P Mischak

Jan Marian Scardina

Guy Rautmann

Corinne Heckel

Chantal Guenet

John Huggins

The invention concerns a compound of general formula (I), wherein: X represents an oxygen or sulphur atom; Rrepresents, independently of each other when n=2 or 3, a halogen atom, a hydroxy, a C-Calkyl, a C-Calkoxy, a trifluoromethyl, a trifluoromethyloxy or a methylenedioxy; Rrepresents a C-Calkyl group optionally substituted, a C-Ccycloalkyl, piperidinyl or phenyl group, the C-Ccycloalkyl, piperidinyl or phenyl groups being optionally substituted; Rrepresents a hydrogen atom or a C-Calkyl group optionally substituted; Rrepresents a hydrogen atom or a C-C4 alkyl group; and Rand Rrepresent, independently of each other, a hydrogen atom, a hydroxy, a halogen atom, a C-Calkyl group, or Rand Rform together an oxo group; Rrepresents a hydrogen atom, a halogen atom, a C-Calkyl, a C-Calkoxy, a trifluoromethyl, or a trifluoromethoxy; in the form of a base, addition to an acid, hydrate or solvate. The invention is applicable in therapy 

Acylaminothiazole derivatives, their preparation and therapeutic use

The invention relates to the design, construction and use of eukaryotic cell lines useful in the identification of inhibitors of &bgr;-amyloid processing. More specifically, the invention relates to in vitro assays capable of identifying or quantifying a 4.2 kDa &bgr;-amyloid protein. The present invention also provides for DNA and protein molecules for the design, construction and use of eukaryotic cell lines useful in the identification of inhibitors of &bgr;-amyloid processing.

Assays for &bgr;-amyloid processing

Growing community of inventors

Strasbourg, France

Rebecca Pruss